Relugolix has 2 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with P-Gp Inhibitors (Oral), Strong Cyp3a4 And P-Glycoprotein Inducers. Patients taking Relugolix should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Major
- 2
Major (2)
- Relugolix + P-Gp Inhibitors (Oral)— Co-administration increases relugolix exposure and risk of adverse reactions. If unavoidable, separate dosing by at leas…
- Relugolix + Strong Cyp3a4 And P-Glycoprotein Inducers— Co-administration decreases relugolix exposure, which may reduce therapeutic effects. If unavoidable, increase ORGOVYX d…